Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601

Published date28 December 2018
Citation83 FR 67287
Record Number2018-28220
SectionNotices
CourtFood And Drug Administration
Federal Register, Volume 83 Issue 248 (Friday, December 28, 2018)
[Federal Register Volume 83, Number 248 (Friday, December 28, 2018)]
                [Notices]
                [Pages 67287-67288]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2018-28220]
                -----------------------------------------------------------------------
                DEPARTMENT OF HEALTH AND HUMAN SERVICES
                Food and Drug Administration
                [Docket No. FDA-2012-N-0536]
                Agency Information Collection Activities; Proposed Collection;
                Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601
                AGENCY: Food and Drug Administration, HHS.
                ACTION: Notice.
                -----------------------------------------------------------------------
                SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
                an opportunity for public comment on the proposed collection of certain
                information by the Agency. Under the Paperwork Reduction Act of 1995
                (PRA), Federal Agencies are required to publish notice in the Federal
                Register concerning each proposed collection of information, including
                each proposed extension of an existing collection of information, and
                to allow 60 days for public comment in response to the notice. This
                notice solicits comments on Form FDA 3601, entitled ``Medical Device
                User Fee Cover Sheet,'' which must be submitted along with certain
                medical device product applications, supplements, and fee payment of
                those applications.
                DATES: Submit either electronic or written comments on the collection
                of information by February 26, 2019.
                ADDRESSES: You may submit comments as follows. Please note that late,
                untimely filed comments will not be considered. Electronic comments
                must be submitted on or before February 26, 2019. The https://www.regulations.gov electronic filing system will accept comments until
                11:59 p.m. Eastern Time at the end of February 26, 2019. Comments
                received by mail/hand delivery/courier (for written/paper submissions)
                will be considered timely if they are postmarked or the delivery
                service acceptance receipt is on or before that date.
                Electronic Submissions
                 Submit electronic comments in the following way:
                 Federal eRulemaking Portal: https://www.regulations.gov.
                Follow the instructions for submitting comments. Comments submitted
                electronically, including attachments, to https://www.regulations.gov
                will be posted to the docket unchanged. Because your comment will be
                made public, you are solely responsible for ensuring that your comment
                does not include any confidential information that you or a third party
                may not wish to be posted, such as medical information, your or anyone
                else's Social Security number, or confidential business information,
                such as a manufacturing process. Please note that if you include your
                name, contact information, or other information that identifies you in
                the body of your comments, that information will be posted on https://www.regulations.gov.
                 If you want to submit a comment with confidential
                information that you do not wish to be made available to the public,
                submit the comment as a written/paper submission and in the manner
                detailed (see ``Written/Paper Submissions'' and ``Instructions'').
                Written/Paper Submissions
                 Submit written/paper submissions as follows:
                 Mail/Hand Delivery/Courier (for written/paper
                submissions): Dockets Management Staff (HFA-305), Food and Drug
                Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
                 For written/paper comments submitted to the Dockets
                Management Staff, FDA will post your comment, as well as any
                attachments, except for information submitted, marked and identified,
                as confidential, if submitted as detailed in ``Instructions.''
                 Instructions: All submissions received must include the Docket No.
                FDA-2012-N-0536 for ``Agency Information Collection Activities;
                Proposed Collection; Comment Request; Medical Device User Fee Cover
                Sheet, Form FDA 3601.'' Received comments, those filed in a timely
                manner (see ADDRESSES), will be placed in the docket and, except for
                those submitted as ``Confidential Submissions,'' publicly viewable at
                https://www.regulations.gov or at the Dockets Management Staff between
                9 a.m. and 4 p.m., Monday through Friday.
                 Confidential Submissions--To submit a comment with
                confidential
                [[Page 67288]]
                information that you do not wish to be made publicly available, submit
                your comments only as a written/paper submission. You should submit two
                copies total. One copy will include the information you claim to be
                confidential with a heading or cover note that states ``THIS DOCUMENT
                CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy,
                including the claimed confidential information, in its consideration of
                comments. The second copy, which will have the claimed confidential
                information redacted/blacked out, will be available for public viewing
                and posted on https://www.regulations.gov. Submit both copies to the
                Dockets Management Staff. If you do not wish your name and contact
                information to be made publicly available, you can provide this
                information on the cover sheet and not in the body of your comments and
                you must identify this information as ``confidential.'' Any information
                marked as ``confidential'' will not be disclosed except in accordance
                with 21 CFR 10.20 and other applicable disclosure law. For more
                information about FDA's posting of comments to public dockets, see 80
                FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
                 Docket: For access to the docket to read background documents or
                the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
                the heading of this document, into the ``Search'' box and follow the
                prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
                Rm. 1061, Rockville, MD 20852.
                FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
                Food and Drug Administration, Three White Flint North, 10A-12M, 11601
                Landsdown St., North Bethesda, MD 20852, 301-796-8867,
                PRAStaff@fda.hhs.gov.
                SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
                Agencies must obtain approval from the Office of Management and Budget
                (OMB) for each collection of information they conduct or sponsor.
                ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
                1320.3(c) and includes Agency requests or requirements that members of
                the public submit reports, keep records, or provide information to a
                third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
                requires Federal Agencies to provide a 60-day notice in the Federal
                Register concerning each proposed collection of information, including
                each proposed extension of an existing collection of information,
                before submitting the collection to OMB for approval. To comply with
                this requirement, FDA is publishing notice of the proposed collection
                of information set forth in this document.
                 With respect to the following collection of information, FDA
                invites comments on these topics: (1) Whether the proposed collection
                of information is necessary for the proper performance of FDA's
                functions, including whether the information will have practical
                utility; (2) the accuracy of FDA's estimate of the burden of the
                proposed collection of information, including the validity of the
                methodology and assumptions used; (3) ways to enhance the quality,
                utility, and clarity of the information to be collected; and (4) ways
                to minimize the burden of the collection of information on respondents,
                including through the use of automated collection techniques, when
                appropriate, and other forms of information technology.
                Medical Device User Fee Cover Sheet, Form FDA 3601
                OMB Control Number 0910-0511--Extension
                 The Federal Food, Drug, and Cosmetic Act, as amended by the Medical
                Device User Fee and Modernization Act of 2002 (Pub. L. 107-250), and
                the Medical Device User Fee Amendments of 2007 (title II of the Food
                and Drug Administration Amendments Act of 2007), authorizes FDA to
                collect user fees for certain medical device applications. Under this
                authority, companies pay a fee for certain new medical device
                applications or supplements submitted to the Agency for review. Because
                the submission of user fees concurrently with applications and
                supplements is required, the review of an application cannot begin
                until the fee is submitted. Form FDA 3601, the ``Medical Device User
                Fee Cover Sheet,'' is designed to provide the minimum necessary
                information to determine whether a fee is required for review of an
                application, to determine the amount of the fee required, and to
                account for and track user fees. The form provides a cross-reference
                between the fees submitted for an application with the actual submitted
                application by using a unique number tracking system. The information
                collected is used by FDA's Center for Devices and Radiological Health
                and the Center for Biologics Evaluation and Research to initiate the
                administrative screening of new medical device applications and
                supplemental applications.
                 The total number of annual responses is based on the average number
                of cover sheet submissions received by FDA in recent years. The number
                of received annual responses includes cover sheets for applications
                that were qualified for small businesses and fee waivers or reductions.
                The estimated hours per response are based on past FDA experience with
                the various cover sheet submissions, and range from 5 to 30 minutes.
                The hours per response are based on the average of these estimates (18
                minutes).
                 FDA estimates the burden of this collection of information as
                follows:
                 Table 1--Estimated Annual Reporting Burden \1\
                ----------------------------------------------------------------------------------------------------------------
                 Number of
                 FDA form No. Number of responses per Total annual Average burden per Total hours
                 respondents respondent responses response
                ----------------------------------------------------------------------------------------------------------------
                3601...................... 6,379 1 6,379 0.30 (18 minutes)... 1,914
                ----------------------------------------------------------------------------------------------------------------
                \1\ There are no capital costs or operating and maintenance costs associated with this collection of
                 information.
                 Our estimated burden for the information collection reflects an
                overall increase of 350 hours and a corresponding increase of 1,165
                responses/records. We attribute this adjustment to an increase in the
                number of submissions we received over the last few years.
                 Dated: December 20, 2018.
                Leslie Kux,
                Associate Commissioner for Policy.
                [FR Doc. 2018-28220 Filed 12-27-18; 8:45 am]
                 BILLING CODE 4164-01-P
                

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT